Study limitation: Adolescents (≥12 years) are included in the approved indication per the SmPC, but the post hoc analysis population age range is not explicitly specified in the abstract | ReachRx
Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis
Study limitation reported by the research below: “Adolescents (≥12 years) are included in the approved indication per the SmPC, but the post hoc analysis population age range is not explicitly specified in the abstract.”
